Biotech Business - March 25, 2026
Tenboron receives EUR 7.6 million EU funding
Tenboron has received a positive funding decision from the European Union Horizon Europe Health 2025 programme for Phase 1 and 2 clinical studies of its TB0010 boron carrier for Boron Neutron Capture Therapy (BNCT).
Agreement - March 25, 2026
Genovis in non-exclusive license agreement with US biotech company
Genovis has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.
Clinical Trials - March 25, 2026
Verigraft initiates Phase II/III trial of its personalized tissue engineered vein
The company has announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insufficiency (CVI), supported by USD 10 million from existing investors.
Business article - March 25, 2026
AI in Nordic life sciences: Less about deals, more about ecosystems
AI-related news from the Nordic life science industry has been less about single blockbuster deals and more about ecosystem-level moves, new initiatives, and investments.
Financing - March 25, 2026
ProteomEdge raises SEK 8 million
The company has announced the completion of a second funding round, led by Navigare Ventures, a subsidiary of Wallenberg Investments, with continued strong participation from existing shareholders.
In a new job - March 25, 2026
The CEO of Mölnlycke resigns
Guillaume Joucla has been appointed interim CEO of Mölnlycke, following Zlatko Rihter's decision to resign after more than five years as CEO.
